03/09/2026
Information on the burden of postacute sequelae following SARS-CoV-2 infection (or long COVID) amongst immunocompromised cancer patients is limited during endemicity.
Researchers from National Cancer Centre Singapore, Singapore General Hospital and Duke-NUS Medical School collaborated to evaluate the risk of long COVID in a population-based cohort of Singaporean cancer patients during Omicron predominance, as part of a multi-centre project of the national Programme for Research in Epidemic Preparedness and REsponse (PREPARE), under the Communicable Diseases Agency.
Their findings suggested that amongst COVID-19 vaccinated/boosted cancer patients, overall risk of long COVID was not significantly elevated, highlighting the continued importance of COVID-19 vaccination amongst immunocompromised cancer patients during endemicity.
Read more in JAMA Network Open, American Medical Association (AMA): https://bit.ly/4vGsAJG
AMC researchers involved: Ian Liang En Wee, Wei Chong Tan, Iain Bee Huat Tan, Kelvin Bryan Tan
Collaborators: Jinghao Nicholas Ngiam, David Chien Boon Lye, Calvin J Chiew (Communicable Diseases Agency, Singapore); Muhammad Ismail Bin Abdul Malek, Russell Jingxian Li (National Centre for Infectious Diseases - NCID); Yong Yi Tan, Jue Tao Lim (NTU Lee Kong Chian School of Medicine); Matilda Lee (National University Cancer Institute, Singapore - NCIS), Elise Kiat Yee Vong (Tan Tock Seng Hospital (TTSH))
Visit Academic Medicine Research Institute - AMRI at https://www.singhealthdukenus.com.sg/research